MediciNova Inc - Company Profile
Powered by 
All the sales intelligence you need on MediciNova Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how MediciNova Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with MediciNova Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
MediciNova Inc (MediciNova) is a biopharmaceutical company. It develops novel therapeutics for serious diseases with unmet medical needs. The company's product pipeline includes MN-166 (ibudilast), MN-001 (tipelukast) and MN-029 (denibulin), targeting a range of neurological, fibrotic, respiratory, and oncological disorders. MediciNova's leading candidate, MN-166 (ibudilast), is under development for progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma and acute respiratory distress syndrome (ARDS). MN-001 (tipelukast) is being developed for fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). MN-029 (denibulin) is focused on solid tumor cancers. MediciNova is headquartered in La Jolla, California, the US.
Headquarters
United States of America
Address
Suite 300, 4275 Executive Square, La Jolla, California, 92037
Website
www.medicinova.com
Telephone
1 858 3731500
No of Employees
6
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
MNOV (NASD)
Revenue (2024)
$409,700
EPS
XYZ
Net Income (2024)
XYZ
-8.6%
(2024 vs 2023)
Market Cap*
$68.9M
Net Profit Margin (2024)
XYZ
0.0%
(2024 vs 2023)
* As of and is in US$
MediciNova Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline: |
| MN-166: Neurological Disorders |
| MN-001: Fibrotic Diseases, Bronchial Asthma and Interstitial Cystitis |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | MediciNova Inc | Sanofi | Amgen Inc | Biogen Inc | Alkermes Plc |
|---|---|---|---|---|---|
| Headquarters | United States of America | France | United States of America | United States of America | Ireland |
| City | La Jolla | Paris | Thousand Oaks | Cambridge | Dublin |
| State/Province | California | Ile-de-France | California | Massachusetts | Dublin |
| No. of Employees | 6 | 76,493 | 31,500 | 7,500 | 2,050 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Yuichi Iwaki, M.D., Ph.D. | Chief Executive Officer; Director; President | Executive Board | 2006 | 75 |
| Kazuko Matsuda, M.D., Ph.D. | Chief Medical Officer; Director | Executive Board | 2011 | 59 |
| Jason J. Kruger | Chief Financial Officer | Senior Management | 2022 | 48 |
| David H. Crean, Ph.D. | Chief Business Officer | Senior Management | 2021 | 60 |
| Geoffrey O'Brien | Executive Officer; Vice President | Senior Management | 2013 | 54 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer